Immunotherapy developer Dynavax explores options for Hepatitis B drug – Nasdaq
|
Immunotherapy developer Dynavax explores options for Hepatitis B drug
Nasdaq Sept 29 (Reuters) – Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strategic options for its hepatitis B vaccine, which could include a potential sale or … |
